Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by March 22, 2013.
Register online, or by phone, fax or mail. Please indicate that you would like to present a poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool. Please see below for more information.
Reasons you should present your research poster at this conference:
- Your poster will be exposed to our international delegation
- Receive $50 off your registration
- Your poster abstract will be published in our conference materials
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes
NOTE: Special poster restrictions apply.
1. Posters will be limited to ONE poster per person.
2. You must select ONE track for your poster. Your poster will hang only for the duration of that track. (Your poster selection must be concurrent with your registration selection, but it does not have to be the same.)
Note: Posters should be portrait orientation, with maximum dimensions of
36 inches wide (3 feet) x 48 inches high (4 feet).
* CHI reserves the right to publish your poster title and abstract in various marketing materials and products.
Click here for poster instructions
Partial List of Confirmed Posters (as of 3/1/2013)
Adocia Platforms for mAb Formulation
AIMlinked Bispecific Antibody Provides Pan-Specific Influenza A protection
An Automated Solution to Antibody Purifications
Antagonistic TNF Receptor One-Specific Antibody (ATROSAB)
Applying Phage Display to Screen a Library of a 1-Protease Inhibitor Mutants for Improved Thrombin Binding Activity
Bacterial Chromosome Engineering for the Optimized Expression of Optimized Proteins
Benefits of Non Cleavable Linkers in Antibody Drug Conjugates
Chemoenzymatic and Site-specific Modification of Proteins
Completely Automated Plasmid Prep & Optimized Protein Separation Using PhyTip Columns
Development and Characterization of a New Anti-Angiogenic Monoclonal Antibodies
Development of a Transiently Protein-Anchored Aystem for High-Throughput Sorting of the Most Productive Protein-Producing Cell
Development of an Anti-Methoxy Polyethylene glycol (a-mPEG) Capture to Measure mPEG or mPEGylated Molecules
Dissecting Cell Signalling Network Rewiring with Synthetic Antibodies
Engineering Bispecific Antibodies and the Implications of Design on Expression Levels, Stability and Binding of Targets
GMP-Ready Human Antibodies for Therapeutic Applications
Half Life Extension Through Novel Glycan Substitutes
Heterologous Expression Profile of YjqC from B. Pumilus.
Human Cytomegalovirus full-length gB produced in BEVS
Improved Expression of a Complex Malaria Vaccine Antigen Through Process Development
Improved Panning Output and Antibody Fragment Production by Co-expression with the Peptidyl Prolyl Isomerase, FkpA, in the Cytoplasm of Escherichia coli
Isolation of Anti-sialic Acid Recombinant Antibodies
Purification of a Recombinant, Truncated Plasminogen by Salting Out Followed by Hydrophobic Interaction Chromatography
Rapid, Multiplexed Microfluidic Phage Display
Remediating Aggregation of an Antibody by Engineered Eradication of Hydrophobic Motifs
Robust in vitro Affinity Maturation Strategy Based on Interface-Focused High-Throughput Mutational Scanning
Shark Antibodies and Human I-bodies as Novel Diagnostics.
Aingle-Round Phage Display Screening via Target-Directed Phage Biotinylation
Size Distribuition Analysis of Vaccines
Structure Based Antibody Engineering
Supporting Research and Drug Development
switchSENSE-Redefining Biomolecular Interaction Analysis
Targeting Glioblastoma by Development of Monoclonal Antibodies Against CSPG4
Targeting Glycans with Lectenz(R) - Engineered Glycan-Binding Biomolecules
The Observation of Phosphoylation Process in Preconjugation Combinations Can Raise the Standard of Antibody Conjugation
TRAIL-Functionalized Immunoliposomes for Tumor Therapy
Transient Antibody Expression
TwoB-Ig; Engineered Antibody Fc Variant with Selectively Enhanced Fc?RIIb Binding Over Both Fc?RIIa (Arg131) and Fc?RIIa (His131)
Vector Free Expression
VRC01 Fc Mutant Can Improve the Protection Against SHIV Challenge in Nonhuman Primate
Yeast-ER-Sequestration Screening (YESS) based Protease Substrate Profiling and Protease Engineering